Shriram Rm 104
Abstract:
Personalized Health Care (PHC) is Roche’s core strategy for developing new medicines against serious diseases. Targeted medicines are developed based on deep understanding of the molecular pathways, evidence-based clinical practice, and diagnostics and biomarkers that help to identify the patient sub-groups most likely to benefit from the treatment. PHC is a key enabler to increase our success rate in the development of drugs that are highly efficacious, have good safety profiles, and provide high-valued outcomes for patients and stakeholders.
This presentation will highlight innovations contributing to the development of several breakthrough medicines in oncology, including monoclonal antibody therapeutics derived from recombinant DNA techniques pioneered by Genentech, an antibody drug conjugate, and small molecule targeted therapies. In addition, a number of product candidates currently under development in the field of cancer immunotherapy will be discussed, as these represent some of today’s most promising approaches to treating cancer. These products involve complex molecular formats such as bispecifics, as well as the new area of personalized cancer vaccines. Insights will be provided into the advances in engineering and technology that are needed to manufacture these drugs, including key process and analytical developments, scale-up techniques, and manufacturing technology innovations.